Characterization of the Immunologic and Anticoagulant Properties of Purified Anti–β2-GPI and Antiprothrombin IgG Antibodies
APL Antibodies . | aβ2-GPI (GPL U) . | aHPT (mOD) . | aHPT/PS (mOD) . | Anticoagulant Activity (s) . | ||
---|---|---|---|---|---|---|
daPTT . | dRVVT . | dRVVT . | ||||
(normal pooled plasma) . | (β2-GPI–deficient plasma) . | |||||
Anti–β2-GPI | ||||||
1. | 170 | 1,923 | 1,817 | 94.8 | 47.6 | 51.3 |
2. | 96 | 1,881 | 2,012 | 67.6 | 35.7 | 49.9 |
3. | 100 | 802 | 1,071 | 67.9 | 41.7 | 50.7 |
4. | 25 | 1,418 | 544 | 61.5 | 35.8 | 51.0 |
Antiprothrombin | ||||||
5. | 1 | 444 | 378 | 89.1 | 40.5 | 59.4 |
6. | 1 | 976 | 1,007 | 84.9 | 39.2 | 73.4 |
7. | 2 | 1,074 | 424 | 70.7 | 32.8 | 67.2 |
8. | 2 | 1,098 | 501 | 89.1 | 40.8 | 76.2 |
Normal IgG | 1 | 238 | 256 | 57.5 | 28.5 | 49.9 |
APL Antibodies . | aβ2-GPI (GPL U) . | aHPT (mOD) . | aHPT/PS (mOD) . | Anticoagulant Activity (s) . | ||
---|---|---|---|---|---|---|
daPTT . | dRVVT . | dRVVT . | ||||
(normal pooled plasma) . | (β2-GPI–deficient plasma) . | |||||
Anti–β2-GPI | ||||||
1. | 170 | 1,923 | 1,817 | 94.8 | 47.6 | 51.3 |
2. | 96 | 1,881 | 2,012 | 67.6 | 35.7 | 49.9 |
3. | 100 | 802 | 1,071 | 67.9 | 41.7 | 50.7 |
4. | 25 | 1,418 | 544 | 61.5 | 35.8 | 51.0 |
Antiprothrombin | ||||||
5. | 1 | 444 | 378 | 89.1 | 40.5 | 59.4 |
6. | 1 | 976 | 1,007 | 84.9 | 39.2 | 73.4 |
7. | 2 | 1,074 | 424 | 70.7 | 32.8 | 67.2 |
8. | 2 | 1,098 | 501 | 89.1 | 40.8 | 76.2 |
Normal IgG | 1 | 238 | 256 | 57.5 | 28.5 | 49.9 |